Complaint Counsel's Post Trial Brief - Federal Trade Commission

352. LaMont acknowledged that there have been no clinical studies perormed on the DCO
Products. (R22 (LaMont, Dep. at 48); LaMont, Tr. 579).
353. The DCO products "are not silver bullets." (R22 (LaMont, Dep. at 127)).
354. LaMont does not know the Feijos. (R22 (LaMont, Dep. at 49)).
their oncologist
and utilze protocols that are proven to be most effective for their cancer and that they
355. LaMont this that it is "best that people follow the recommendations of
should be well-informed of the potential value of the aray of other therapies." (R22
(LaMont, Dep. at 49)).
I'm workig with a patient, I'm going to insist that
they work with their oncologist and follow their advice and I'm going to comanage their
care." (R22 (LaMont, Dep. at 51-52)).
356. LaMont testified that "as a doctor, if
plant
foods and medicines should not influence patients with cancer and other serous diseases
to abandon using the most effective methods that moder medicine has to offer." (R22
(LaMont, Dep. at 52)).
357. LaMont believes that "(t)he awareness of the powerl chemoprotective effects of
358. LaMont would not be comfortable with the Feijos sayig that the DCO products are
going to cure cancer. (R22 (LaMont, Dep. at 53)).
359. LaMont can see why the Federal Trade Commission would have concers about the
statement that DCO's products are cancer solutions. (R22 (LaMont, Dep. at 127)).
360. LaMont would not have wrtten the text that way to include "cancer solutions" next to the
DCO products. (R22 (LaMont, Dep. at 128)).
361. LaMont does not "believe that on their own across the board these (DCO) products are
going to effectively treat cancer." (R22 (LaMont, Dep. at 53)).
362. LaMont did not listen to the Feijo's radio show nor did she have the interest in listenig
to their show. (R22 (LaMont, Dep. at 77)).
that she would defend the DCO products because she has limted
363. LaMont did not say
knowledge of their products. (R22 (LaMont, Dep. at 78)).
364. LaMont has never used the DCO products. (R22 (LaMont, Dep. at 78); LaMont, Tr. 578­
79).
365. LaMont has not studied the DCO products specifically. (R22 (LaMont, Dep. at 87-88);
LaMont, Tr. 579).
366. LaMont acknowledges that traditional use evidence does not replace human clinical
trals. (R22 (LaMont, Dep. at 89); LaMont, Tr. 584).
367. LaMont acknowledges that it is not a common occurence in the industr to make cancer
cure or cancer treatment claims. (R22 (LaMont, Dep. at 144-45)).
32